Effect of Omadacycline on Cardiac Parameters in ABSSSI and CABP
There was no clinically relevant changes in electrocardiography and blood pressure in either study group.
|This article is part of Infectious Disease Advisor's in-depth coverage of IDWeek 2017™, which took place in San Diego, CA. Our staff will be reporting on the latest treatment advancements and research initiatives for skin infections. Check back regularly for highlights from IDWeek 2017.|
|Visit Infectious Disease Advisor's conference section for in-depth coverage from IDWeek 2017.|
Darpo B, Tzanis E, Garrity-Ryan L, Manley A, McGovern P, Loh E. Cardiac safety of omadacycline in the IV/oral phase 3 acute bacterial skin and skin structure infection (ABSSSI) and in the IV/oral phase 3 community-acquired bacterial pneumonia (CABP) studies. Presented at: IDWeek 2017; October 4-8, 2017; San Diego, CA. Poster 1886.